IP Library Granted Patent US 9,061,077
Granted Patent B2
US 9,061,077 · App. 12/990,144 · Granted Jun 23, 2015

Methods of determining renal function using technetium-99m tricarbonyl-nitrilotriacetic acid

Inventors: Malgorzata Lipowska (Decatur, GA); Andrew T. Taylor, Jr. (Atlanta, GA); Luigi Marzilli (Baton Rouge, LA)
Assignee: Emory University
A61K51/0478A61K49/0004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,061,077
App. No.
12/990,144
Granted
Jun 23, 2015
Kind
B2
Abstract

This disclosure relates to the methods of imaging the kidneys and measuring renal function using the renal tracer 99m Tc(CO) 3 (NTA) (technetium-99m tricarbonyl-nitrilotriacetic acid). The disclosure encompasses methods of imaging the kidneys and measuring effective renal plasma flow (ERPF) in an animal or human subject using renal scintigraphy, comprising administering to an animal or human subject an amount of a renal tracer, wherein the renal tracer comprises 99m Tc-(CO) 3 (NTA). Another aspect of the disclosure are methods of measuring effective renal plasma flow in an animal or human subject, comprising administering to an animal or human subject an amount of a renal tracer, wherein the renal tracer comprises 99m Tc-(CO) 3 (NTA), isolating a series of plasma samples from the animal or human subject after administering the renal tracer and quantitatively detecting the amount of the renal tracer in the biological samples.

Claims (30)

1. A method of imaging a kidney in an animal or human subject, the method comprising:

(a) administering to an animal or human subject an amount of a renal tracer, wherein the renal tracer comprises technetium-99m tricarbonyl-nitrilotriacetic acid ( 99m Tc(CO) 3 (NTA));

(b) detecting 99m Tc(CO) 3 (NTA) in the kidney of the animal or human subject with a gamma camera; and

(c) obtaining at least one image of the kidney of the animal or human subject, wherein the image is obtained as a data output from a gamma camera.

2. The method of claim 1 , further comprising periodically repeating the steps (a)-(c), thereby providing a time-dependent analysis of the urinary tract function of an animal or human subject, wherein the analysis is selected from the group consisting of: the EPRF of a kidney, the ability of a kidney to extract the tracer from the blood, the ability of the subject human or animal to excrete the tracer into the collecting system of a kidney, the monitoring of drainage of the tracer from the collecting system (calyces and pelvis) to the bladder, and the quantification of the ability of the bladder to empty.

3. The method of claim 2 , wherein the steps (a)-(c) are repeated at time intervals over a period of about 2 min to 60 mins, thereby providing a time-dependent series of images.

4. The method of claim 2 , wherein the steps (a)-(c) are repeated at time intervals over a period of about 3 min to 60 mins, thereby providing a time-dependent series of images.

5. A method of measuring effective renal plasma flow in an animal or human subject, the method comprising:

(a) administering to an animal or human subject an amount of a renal tracer, wherein the renal tracer comprises 99m Tc(CO) 3 (NTA);

(c) obtaining at least one image of a kidney of the animal or human subject, wherein the image is obtained as a data output from a gamma camera; and

(d) analyzing the data output from the gamma camera, wherein the data analysis provides a measurement of the effective renal plasma flow of the animal or human subject.

6. A method of measuring effective renal plasma flow in an animal or human subject, comprising:

administering to an animal or human subject a dose amount of a composition, wherein the composition comprises the renal tracer 99m Tc(CO) 3 (NTA);

isolating a plurality of biological samples from the animal or human subject after administering the renal tracer;

quantitatively measuring the amount of the renal tracer in the isolated biological samples; and

determining the effective renal plasma flow of the animal or human subject.

7. The method of claim 6 , wherein the biological sample is a plasma sample.

8. A kit comprising: an amount of the tracer 99m Tc(CO) 3 (NTA) in a sealed container, wherein the amount of the tracer is suitable for imaging a kidney of an animal or human subject, and instructions for the use thereof in imaging said kidney, the instructions comprising the steps of:

administering to an animal or human subject an amount of a renal tracer, wherein the renal tracer comprise the renal tracer technetium-99m tricarbonyl-nitrilotriacetic acid ( 99m Tc(CO) 3 (NTA));

detecting 99m Tc(CO) 3 (NTA) in the kidney of the animal or human subject with a gamma camera; and

obtaining at least one image of the kidney of the animal or human subject, wherein the image is obtained as a data output from a gamma camera.

9. The kit according to claim 8 , wherein the instructions further comprise steps for the use of the tracer in measuring renal function, the instructions further comprising the step of:

administering to an animal or human subject an amount of a renal tracer, wherein the renal tracer comprises 99m Tc-(CO) 3 (NTA);

obtaining at least one image of a kidney of the animal or human subject, wherein the image is obtained as a data output from a gamma camera; and

analyzing the data output from the gamma camera, wherein the data analysis provides a measurement of the effective renal plasma flow of the animal or human subject.

10. The kit according to claim 8 , wherein the instructions further comprise the steps for the use of the tracer in measuring renal function, the instructions further comprising the steps of:

administering to an animal or human subject an amount of a renal tracer, wherein the renal tracer comprises 99m Tc-(CO) 3 (NTA);

isolating a plurality of biological samples from the animal or human subject after administering the renal tracer;

quantitatively measuring the amount of the renal tracer in the isolated biological samples; and

determining the effective renal plasma flow of the animal or human subject.

Assignments (5)
CONFIRMATORY LICENSE Recorded Dec 30, 2013
From: EMORY UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031872/0236 →
CONFIRMATORY LICENSE Recorded May 23, 2013
From: EMORY UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030486/0548 →
CONFIRMATORY LICENSE Recorded May 15, 2013
From: EMORY UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030423/0661 →
CONFIRMATORY LICENSE Recorded Apr 26, 2011
From: EMORY UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026178/0946 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2010
From: LIPOWSKA, MALGORZATA; TAYLOR, ANDREW T, JR; MARZILLI, LUIGI
To: EMORY UNIVERSITY
Reel/Frame 025410/0215 →
Continuity (3)
Provisional Application 61151672 · Feb 11, 2009
Provisional Application 61050349 · May 5, 2008
Related Publication 20110064656A1 · Mar 17, 2011